If you are interested to learn more on Pepticom’s AI peptide design & discovery technology, please contact Shoshi.Keynan@wordpress-544837-1818586.cloudwaysapps.com
In the news: https://www.kan.org.il/Item/?itemId=69208
to identify novel inhibitors that can fight the COVID19. We are looking for partners to validate and develop these peptide drug candidates. For more information: firstname.lastname@example.org
https://www.israel21c.org/30-israeli-medical-tech-solutions-to-help-fight-coronavirus/ For more information : Shoshi.Keynan@wordpress-544837-1818586.cloudwaysapps.com
Meet us and learn how Pepticom’s AI peptide design platform can augment your drug discovery process. For more information: email@example.com
Pepticom’s AI peptide design platform as part of “Lead Identification” in the drug discovery ecosystem
Pepticom to present at the Artificial Intelligence and Machine Learning for Advanced Drug Discovery and Development Conference in London, May 28-29.
Pepticom’s CTO, Dr. Amit Michaeli, will present at the Artificial Intelligence and Machine Learning for Advanced Drug Discovery and Development Conference in London, May 28-29.
Pepticom is pleased to welcome Dr. Waleed Danho to its Scientific Advisory Board. Dr. Waleed Danho held the position of Distinguished Research Leader at Hoffmann-La Roche Inc. in Nutley, New Jersey, USA. until April 2011. He is a reviewer for the Journal of Peptide Research, QSAR & Combinatorial Science and the Journal of Medicinal Chemistry; […]
Pepticom is delighted to present our latest article, published in the Journal of Immunology, on the subject of Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist Activity. To the best of our knowledge, this is the first example of using Artificial Intelligence for the discovery of novel cyclic peptides; the discovery effort yielded 53 […]
Dr. Immanuel Lerner, Pepticom’s CEO, will present at “DISCOVERY on TARGET” Conference in Boston (September 25-28).
Dr. Lerner will discuss Pepticom’s exciting design work on TLR4 activators in “the Cyclic Peptide Design Challenges” session.